ATEA PHARMACEUTICALS, INC.

(AVIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about ATEA PHARMACEUTICALS, INC.
05/10TRANSCRIPT : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/10Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
AQ
05/03Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
AQ
03/294794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
PU
03/294793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
PU
03/28Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci..
AQ
03/02JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra..
MT
03/01SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per..
MT
02/28ATEA PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2021 Financial Results and Pro..
PU
02/28Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31..
CI
02/28TRANSCRIPT : Atea Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 28, 2022
CI
02/28ATEA PHARMACEUTICALS : Fourth Quarter 2021 Financial Results Conference Call Presentation
PU
02/28Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Decemb..
CI
02/28Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Pr..
AQ
More most relevant news
All news about ATEA PHARMACEUTICALS, INC.
05/10ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10TRANSCRIPT : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/10Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
AQ
05/03Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
AQ
03/294794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
PU
03/294793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
PU
03/28Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci..
AQ
03/02JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra..
MT
03/01SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per..
MT
More news
News in other languages on ATEA PHARMACEUTICALS, INC.
05/10Atea Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 m..
02/28Atea Pharmaceuticals, Inc. publie ses résultats pour l'année complète se terminant le 3..
02/28Atea Pharmaceuticals, Inc. annonce ses résultats pour le quatrième trimestre clos le 31..
02/10Atea Pharmaceuticals, Inc. annonce des changements de direction
02/02Atea Pharmaceuticals, Inc. annonce la publication dans Nature Communications de données..
01/07Atea Pharmaceuticals, Inc. fait le point sur les priorités de développement clinique de..
2021Atea Pharmaceuticals va être ajouté à l'indice Nasdaq Biotech
2021ROCHE : feu vert européen pour le tocilizumab contre le Covid-19
2021Les actions du secteur de la santé affichent des gains modestes mercredi
2021Les actions du secteur de la santé en hausse modérée cet après-midi
More news
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
03/02JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra..
MT
03/01SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per..
MT
02/16SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $10 from $11, Maintains Marke..
MT
02/01Morgan Stanley Adjusts Atea Pharmaceuticals Price Target to $6 From $7, Reiterates Unde..
MT
01/06Morgan Stanley Downgrades Atea Pharmaceuticals to Underweight From Equal Weight, Adjust..
MT
More recommendations
Press releases
05/10ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
AQ
05/03Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
AQ
03/294794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
PU
03/294793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
PU
More press releases
Upcoming event on ATEA PHARMACEUTICALS, INC.